Subscribe
Jo Panuwat D / Shutterstock.com
24 September 2024NewsAmericasLiz Hockley

Court denies Regeneron bid to halt copy of blockbuster eye drug

Biotech’s motion for preliminary injunction to prevent Eylea biosimilar rejected I Regeneron has filed multiple suits over rivals’ copies of aflibercept.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Regeneron targets almost 50 patents in suit against Sandoz
29 August 2024   Regeneron accused the Swiss pharma company of infringing a slew of patents related to Eylea and violating the BPCIA | Suit alleges that Sandoz failed to provide critical information during the approval process for its newly FDA-approved biosimilar | Sandoz “forced” Regeneron to guess which patents might be infringed.
Big Pharma
Regeneron sues Amgen over biosimilar version of blockbuster eye drug
16 January 2024   US biotech has launched multiple suits over alleged infringement of Eylea patents | Regeneron asks US court to block Amgen’s biosimilar before potential approval.


Editor's picks

Trouble at the USPTO—Part II: Bracing for impact
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025

Editor's picks

Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025
Americas
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’
6 March 2025
Careers
Jones Day adds experienced patent litigators from Weil
4 March 2025
Americas
LSPN finalists revealed for first-ever US awards
3 March 2025
Europe
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
27 February 2025

More on this story

Americas
Regeneron targets almost 50 patents in suit against Sandoz
29 August 2024   Regeneron accused the Swiss pharma company of infringing a slew of patents related to Eylea and violating the BPCIA | Suit alleges that Sandoz failed to provide critical information during the approval process for its newly FDA-approved biosimilar | Sandoz “forced” Regeneron to guess which patents might be infringed.
Big Pharma
Regeneron sues Amgen over biosimilar version of blockbuster eye drug
16 January 2024   US biotech has launched multiple suits over alleged infringement of Eylea patents | Regeneron asks US court to block Amgen’s biosimilar before potential approval.

More on this story

Americas
Regeneron targets almost 50 patents in suit against Sandoz
29 August 2024   Regeneron accused the Swiss pharma company of infringing a slew of patents related to Eylea and violating the BPCIA | Suit alleges that Sandoz failed to provide critical information during the approval process for its newly FDA-approved biosimilar | Sandoz “forced” Regeneron to guess which patents might be infringed.
Big Pharma
Regeneron sues Amgen over biosimilar version of blockbuster eye drug
16 January 2024   US biotech has launched multiple suits over alleged infringement of Eylea patents | Regeneron asks US court to block Amgen’s biosimilar before potential approval.

More features

‘Always new twists’: Bayer legal team on defending a $4bn drug
Novartis and MSN feud intensifies after Fed Circ denies rehearing
EU court signals tough stance on ‘pay-for-delay’ pharma deals
Panitch Schwarze hires experienced ex-USPTO examiner
Fed Circ affirms generic’s litigation costs of $12m are tax-deductible
Genmab fights claim over 'secrets theft' behind $1.8bn takeover
Interpreting the SPC manufacturing waiver: EU courts diverge
European court upholds 10x patent after Nanostring appealed injunction